Bruce E. Hillner, MD
Hillner BE. Anastrozole had a better risk–benefit profile than tamoxifen as adjuvant treatment for breast cancer in postmenopausal women. ACP J Club. 2007;146:4. doi: 10.7326/ACPJC-2007-146-1-004
Download citation file:
Published: ACP J Club 2007;146(1):4.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use